Back to Search
Start Over
Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer
- Source :
- Olsen, D A, Jakobsen, E H & Brandslund, I 2013, ' Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer ', Clinical Chemistry and Laboratory Medicine, vol. 51, no. 12, pp. 2325-2329 . https://doi.org/10.1515/cclm-2013-0166
- Publication Year :
- 2013
-
Abstract
- Background Gene amplification of HER2 (human epidermal growth factor receptor 2) is a well-known phenomenon in various cancers. However, little is known about the mechanism of the gene amplification phenomenon itself. Autoantibodies to cellular receptors have been described in several cancer types. We hypothesised that autoantibodies against HER2 might have a stimulatory capacity and could be the cause of the HER2 gene amplification phenomenon. To investigate this, we developed a test for the detection of autoantibodies against HER2 in serum (S-HER2Ab). Methods Blood and tissue samples were collected from 311 women consecutively admitted for surgical treatment of primary breast cancer. Paraffin embedded tissue sections were analysed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). HER2 protein concentrations in tissue were determined in 115 patients. Circulating extracellular domain of HER2 (S-HER2) was measured using the Advia Centaur (Siemens AG, Munich, Germany). Analysis for autoantibodies was developed on an ImmunoCAP 100 (Phadia AB, Uppsala, Sweden) with an automated Fluorescent Enzyme Immuno Assay. Results Of 311 women, 55 (17.7%) had HER2Ab and 51 (16.4%) showed amplification of the HER2 gene determined by IHC/FISH. Eleven women had detectable S-HER2Ab as well as HER2 gene amplification, but no statistically significant correlation was found between the two phenomena. A significantly higher level of S-HER2Ab was found both in HER2 gene-amplified and non-amplified breast cancer patients compared to an age-matched healthy control group. No statistically significant difference in presence or concentration of S-HER2Ab was found in HER2 gene-amplified vs. non-amplified breast cancer. Conclusions S-HER2Ab can be measured accurately with the ImmunoCAP 100. There is an increased prevalence and concentration of S-HER2Ab in breast cancer patients but no correlation with HER2 gene amplification. We conclude that autoantibodies against HER2 do not seem to be the cause of HER2 gene amplification.
- Subjects :
- Adult
Receptor, ErbB-2
EGFR
Clinical Biochemistry
Blotting, Western
Breast Neoplasms
Enzyme-Linked Immunosorbent Assay
Biology
ErbB2 gene amplification
Breast cancer
ErbB Receptors/immunology
Gene duplication
Breast Neoplasms/blood
ERBB2 Gene Amplification
medicine
Humans
Receptor
skin and connective tissue diseases
Autoantibodies
Aged
Aged, 80 and over
medicine.diagnostic_test
Biochemistry (medical)
Autoantibody
Cancer
General Medicine
Middle Aged
medicine.disease
Molecular biology
Receptor, ErbB-2/genetics
ErbB Receptors
Immunohistochemistry
ELISA
Female
Autoantibodies/blood
Fluorescence in situ hybridization
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Olsen, D A, Jakobsen, E H & Brandslund, I 2013, ' Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer ', Clinical Chemistry and Laboratory Medicine, vol. 51, no. 12, pp. 2325-2329 . https://doi.org/10.1515/cclm-2013-0166
- Accession number :
- edsair.doi.dedup.....07e755be0d80ad5848f86008b04336f9